In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 48, Issue 3, 2004, Pages 201-205

  Pfaller, M A ^a   Messer, S A ^a   Boyken, L ^a   Hollis, R J ^a   Rice, C ^a   Tendolkar, S ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Posaconazole; Surveillance; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGY, MOLECULAR; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES; PROBABILITY; PYRIMIDINES; SENSITIVITY AND SPECIFICITY; TRIAZOLES; WORLD HEALTH;

EID: 1542509561     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.09.008     Document Type: Article

References (18)

1. Barchiesi F., Arzeni D., Fothergill A.W., et al. In vitro activities of the new antifungal triazoles S. C.H. 56592 against common and emerging pathogens. Antimicrob Agents Chemother. 44:2000;226-229.
2. Barry A.L., Pfaller M.A., Brown S.D., et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol. 38:2000;3457-3459.
3. Espinel-Ingroff A. Comparison of in vitro activities of the new triazoles SCH 56592 and the echinocandins MK-0991 (L-743, 872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:1998;2950-2956.
4. Espinel-Ingroff A., Boyle K., Sheehan D.J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods review of the literature. Mycopatholgia. 150:2001;101-115.
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution testing of yeasts. Approved standard-second edition M27-A2. 2002;NCCLS, Wayne, PA.
6. Petraitiene R., Petraitis V., Groll A.H., et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 45:2001;857-869.
7. Pfaller M.A., Zhang J., Messer S.A., et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 556 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 43:1999;169-171.
8. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3, 685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother. 45:2001;2862-2864.
9. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., Messer S.A., The SENTRY Participant Group. International surveillance of bloodstream infections due to Candida species frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol. 39:2001;3254-3259.
10. Pfaller M.A., Diekema D.J. Role of sentinel surveillance in candidemia trends in species distribution and antifungal susceptibility. J Clin Microbiol. 40:2002;3551-3557.
11. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Diekema D.J. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6, 970 clinical isolated of Candida spp. Antimicrob Agents Chemother. 46:2001;1723-1727.
12. Pfaller M.A., Diekema D.J., Jones R.N., Messer S.A., Hollis R.J., The SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp isolated from pediatric and adult patients with bloodstream infections SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 40:2002;852-856.
13. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., The SENTRY Participant Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp and other filamentous fungi report from the SENTRY Antimicriobial Surveillance Program, 2000. Antimicrob Agents Chemother. 46:2002;1032-1037.
14. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., Jones R.N., The International Fungal Surveillance Participant Group. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candia species infrequently isolated from blood. J Clin Microbiol. 41:2003;78-83.
15. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Development of interpretative breakpoints for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole and itraconazole. Clin Infect Dis. 24:1997;235-247.
16. Sabo J.A., Abdel-Rahman S.M. Voriconazole a new triazole antifungal. Ann Phamacother. 34:2000;1032-1043.
17. Verweij P.E., DePauw R.W., Meis J.F. Voriconazole. Curr Opin Anti-Infect Investig Drugs. 1:1999;361-372.
18. Warren N.G., Hazen K.C. Candida, Cryptococcus and other yeasts of medical importance. Murray P.R., Barron, Pfaller M.A., Tenover F.C., Yolken R.H. Manual of Clinical Microbiology. 7th:1999;ASM Press, Washington, DC. pp. 1184-1199.